Human Papillomavirus (HPV) Reagents

Research-grade reagents for Human Papillomavirus (HPV) — a non-enveloped, double-stranded DNA virus and the most common sexually transmitted infection worldwide. High-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are the causative agents of cervical, oropharyngeal, anal, and other anogenital cancers, while low-risk types (6, 11) cause benign anogenital warts. The icosahedral capsid is composed of major capsid protein L1 (the immunodominant target of prophylactic VLP-based vaccines) and minor capsid protein L2 (a target for next-generation broadly protective vaccine strategies). Oncoproteins E6 and E7 drive malignant transformation through p53 degradation and Rb inactivation, making them the principal targets for therapeutic vaccines and immunotherapies. We offer recombinant antibodies & nanobodies, a reference antibody (research biosimilar), InVivoMAb functional-grade antibodies, polyclonal antibodies, and recombinant proteins spanning 14 HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) — covering all 9-valent vaccine types plus additional high-risk genotypes — validated for ELISA, Western blot, neutralization, and functional studies. Comprehensive coverage of L1, L2, E6, E7, and E2 targets supports prophylactic and therapeutic vaccine development, genotype-specific serodiagnostic assay design, neutralization potency testing, oncoprotein-targeted immunotherapy research, and HPV biology studies. RUO

Recombinant Antibodies & Nanobodies An exceptionally deep panel of genotype-specific clones targeting L1 major capsid protein across HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 (including well-characterized neutralizing clones H16.V5, H16.U4, H16.001), L2 minor capsid protein (MAb24B), and extensive E7 oncoprotein coverage across 14 high-risk and low-risk genotypes (HPV16/18/31/33/35/39/45/51/52/56/58/59). E6 oncoprotein clones include conventional recombinant antibodies and VHH nanobodies for intracellular targeting applications. Suitable for genotype-specific pseudovirus neutralization assays, VLP quality control, vaccine potency testing, and oncoprotein detection in HPV-associated malignancies.

Reference Antibody (Research Biosimilar) Research-grade analog of the anti-HPV18 L1 therapeutic antibody (H18L1-A). Suitable for mechanism-of-action studies, competitive binding assays, and as a benchmarking standard for HPV18 neutralizing antibody evaluation in next-generation vaccine development programs.

InVivoMAb Functional-Grade Low-endotoxin, azide-free neutralizing antibodies targeting L1 major capsid protein of HPV58, HPV6, and HPV59, plus L2 minor capsid protein of HPV16. The anti-L2 clones are particularly valuable for evaluating broadly protective immunity, as L2-directed antibodies confer cross-genotype neutralization — a key strategy in next-generation HPV vaccine design aimed at coverage beyond current VLP-based vaccines.

Polyclonal Antibodies Broad-spectrum detection reagents for L1 (HPV16, 18, 56, 59), L2 (HPV16), E6 (HPV16, 18, 52), and E7 (HPV16, 18, 31, 52, 56, 58, 59) across multiple high-risk and low-risk genotypes. Validated for Western blot and ELISA. Suitable for oncoprotein expression profiling in cervical biopsies, genotype-specific antigen detection, and as primary detection reagents in immunohistochemistry panels for HPV-associated cancers.

Recombinant Proteins His-tagged, GST-tagged, SUMO-tagged, and Strep-tagged HPV antigens covering L1 capsid (HPV16, 18, 56, 58, 59, multiple tag formats), L2 minor capsid (HPV16), oncoproteins E6 (HPV16, 18, 52) and E7 (HPV6, 16, 18, 31, 52, 56, 58, 59), and the E2 transcriptional regulator (HPV16). Validated for SDS-PAGE and Western blot. Suitable as coating antigens for seroepidemiological surveys, immunogens for antibody generation, substrates for E6/E7 functional studies, and reference standards for VLP vaccine potency and immunogenicity testing.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012;10(10):681-692. DOI

2. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-560. DOI

3. Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer. 2018;18(4):240-254. DOI

4. Wang JW, Roden RBS. L2, the minor capsid protein of papillomavirus. Virology. 2013;445(1-2):175-186. DOI